Millennium Management LLC Invests $4.13 Million in Perspective Therapeutics, Inc. (NYSE:CATX)

Millennium Management LLC purchased a new position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,295,343 shares of the company's stock, valued at approximately $4,132,000. Millennium Management LLC owned 1.92% of Perspective Therapeutics as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in CATX. Affinity Asset Advisors LLC lifted its holdings in Perspective Therapeutics by 160.0% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company's stock valued at $4,147,000 after purchasing an additional 800,000 shares in the last quarter. Walleye Capital LLC lifted its holdings in shares of Perspective Therapeutics by 2,526.2% in the fourth quarter. Walleye Capital LLC now owns 475,792 shares of the company's stock worth $1,518,000 after buying an additional 457,675 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Perspective Therapeutics in the fourth quarter worth $834,000. Jump Financial LLC purchased a new position in shares of Perspective Therapeutics in the fourth quarter worth $688,000. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Perspective Therapeutics in the fourth quarter worth $418,000. 54.66% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Perspective Therapeutics

In other Perspective Therapeutics news, CEO Johan M. Spoor bought 22,026 shares of Perspective Therapeutics stock in a transaction that occurred on Friday, March 28th. The shares were purchased at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the transaction, the chief executive officer now owns 59,383 shares of the company's stock, valued at $133,017.92. This represents a 58.96% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Juan Graham bought 33,333 shares of Perspective Therapeutics stock in a transaction that occurred on Friday, March 28th. The shares were acquired at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the transaction, the chief financial officer now directly owns 35,354 shares of the company's stock, valued at $79,546.50. This trade represents a 1,649.33% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 115,696 shares of company stock valued at $256,344. Insiders own 3.52% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on CATX. Royal Bank of Canada lowered their target price on shares of Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating on the stock in a report on Thursday, March 27th. HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Perspective Therapeutics in a research report on Monday, March 31st. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price objective on the stock. Brookline Capital Management upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a report on Monday, March 10th. Finally, Wedbush reiterated an "outperform" rating and set a $11.00 target price on shares of Perspective Therapeutics in a report on Tuesday, May 13th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $12.50.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock traded down $0.13 during trading hours on Friday, hitting $2.57. 587,171 shares of the company were exchanged, compared to its average volume of 1,031,685. Perspective Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $16.55. The business has a 50-day moving average of $2.25 and a 200-day moving average of $3.07.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.